Immunohistochemistry (IHC) : Formalin-fixed, paraffin-embedded human breast carcinoma stained with anti-VEGF antibody using peroxidase-conjugate and DAB chromogen. Note the cell surface and cytoplasmic staining of tumor cells

rabbit anti-VEGF monoclonal antibody (ZR389) 6401

$160.00 – $528.00

Antibody summary

Rabbit monoclonal to VEGF
Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
Reacts with: Human
Isotype:IgG
Control: Tumor cells in astrocytomas, breast or ovarian carcinomas
Visualization: Cytoplasm, cell surface
0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted

SKU: 6401parent Category: antibody Tags: anatomy, General & Epithelial Markers, VEGF

Weight	1 lbs
Dimensions	9 × 5 × 2 in
host	mouse
isotype	IgG
clonality	monoclonal
concentration	concentrate, predilute
applications	IHC
reactivity	human
available size	0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted

rabbit anti-VEGF monoclonal antibody ZR389 6401

antibody
Database link: human P15692
Tested applications IHC
Recommended dilutions As directed
Immunogen Recombinant fragment (around aa1-200) of human VEGFA protein (exact sequence is proprietary)
Size and concentration 7 mL prediluted or 0.1, 0.5, 1.0 mL and concentrated
Form liquid
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Purity affinity purified
Clonality monoclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit polyclonal - Isotype Control

target relevance
Protein names Vascular endothelial growth factor A, long form (L-VEGF) (Vascular permeability factor) (VPF) [Cleaved into: N-VEGF; VEGFA]
Gene names VEGFA,VEGFA VEGF
Protein family PDGF/VEGF growth factor family
Mass 9606Da
Function [N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity).; [VEGFA]: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth (PubMed:34530889). Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437).; [Isoform VEGF165B]: Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Subellular location [N-VEGF]: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxic conditions and localizes to the nucleus under hypoxic conditions.; [VEGFA]: Secreted .; [Isoform L-VEGF189]: Endoplasmic reticulum. Golgi apparatus. Secreted, extracellular space, extracellular matrix .; [Isoform VEGF121]: Secreted .; [Isoform VEGF165]: Secreted .; [Isoform VEGF189]: Secreted. Note=Cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
Tissues Higher expression in pituitary tumors than the pituitary gland.; [Isoform VEGF189]: Widely expressed.; [Isoform VEGF165]: Widely expressed.; [Isoform VEGF121]: Widely expressed.; [Isoform VEGF206]: Not widely expressed.; [Isoform VEGF145]: Not widely expressed.
Structure [VEGFA]: Homodimer; disulfide-linked (By similarity). Also found as heterodimer with PGF (By similarity). Interacts with NRP1 (PubMed:26503042). Interacts with isoform 2 of BSG (PubMed:25825981). Interacts with CD82; this interaction inhibits VEGFA-mediated signaling pathway (PubMed:34530889).
Post-translational modification [Vascular endothelial growth factor A, long form]: Produced by use of an alternative upstream CUG codon and post-translationally processed into the N-terminal N-VEGF form and the C-terminal secreted VEGFA form.
Involvement in disease DISEASE: Microvascular complications of diabetes 1 (MVCD1) [MIM:603933]: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.
Target Relevance information above includes information from UniProt accession: P15692
The UniProt Consortium

Data

Formalin-fixed, paraffin-embedded human breast carcinoma stained with anti-VEGF antibody using peroxidase-conjugate and DAB chromogen. Note the cell surface and cytoplasmic staining of tumor cells

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.